TB-500 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-04-13. Where a claim depends on a specific study, the study is described rather than over-claimed.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
TB-500 is a laboratory label applied to a short synthetic peptide that is widely described as a fragment of thymosin beta-4, an actin-binding protein present in most mammalian cells. Suppliers and review articles usually present TB-500 as the N-terminal region of that protein, but the exact sequence attached to the name is not consistent across sources. Some product descriptions list a seven-residue chain; others use the label loosely for the parent protein itself. Because of that variation, any technical discussion of TB-500 needs to state which sequence is meant.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Thymosin beta-4 fragment; TB4 fragment | Naming is inconsistent across suppliers and publications |
| Reported sequence | Ac-LKKTETQ | Corresponds to residues 17-23 of the parent protein |
| Frequently cited registry number | 77591-33-4 | Associated with full-length thymosin beta-4 rather than the fragment |
| Common supplied form | Freeze-dried solid | Often presented as an acetate or trifluoroacetate salt |
| Regulatory treatment | Varies by country | Frequently handled as a research chemical; not broadly approved as a therapeutic |
Lyophilised material is stable for extended periods when kept dry and cold, and suppliers typically recommend storage well below freezing. Once dissolved, the peptide is handled at refrigeration temperatures and used within a short period, because peptide bonds and the acetylated terminus can be affected by repeated freeze-thaw cycles, proteases, or extreme pH. Bacteriostatic water and saline are both described as solvents, although preservatives can interfere with some analytical workflows. Reconstituted solutions are inspected for particulates before use.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
==== Cooperation with capitalist law ==== Despite calling for the establishment of socialist political parties, Socialist Studies believes that such parties should not engage in political action which requires use of or active cooperation with what they call "capitalist law" or "bourgeois legislation". This arises from their interpretation of Clause 8 of their Declaration of Principles. That clause states that "Socialist Studies [...] enters the field of political action". The group interprets this as specifically excluding "legal or moral action" and as "overrid[ing] any other consideration". In light of this, they accuse the SPGB of being capitalist collaborators for having registered with the Electoral Commission, which is a legal requirement to contest elections in the United Kingdom. Nonetheless, members of the group had previously registered as candidates for parliamentary and council elections when they were members of the SPGB and the group itself eventually registered with the Electoral Commission. The group as a whole has also occasionally appealed to the state's legal institutions, such as their 1994 lawsuit against the Britannia Building Society. They have also accused others of "criminal libel" and have repeatedly indicated that they are prepared to sue, if necessary.
Cushing also stated that Eddy was "a very interesting patient" who was "one of the most sensitive to the effects" of the morphine that he ever saw, and that to his surprise, the dose put her "sound asleep." Her husband Daniel Patterson was out of town at the time, but she was attended to by friends, Carrie Millett and Mary Wheeler, who took turns watching by her bedside. They told neighbors that Eddy had broken her back, was paralyzed, and possibly close to death; and at some point a call was made for a minister to come. After that Friday, Eddy apparently refused to take any more of his medicine, having lost her faith in homeopathy. On Sunday, February 4, she sent everyone out of the room and, according to her own account, she opened her Bible and read. She later wrote: "As I read, the healing Truth dawned upon my sense; and the result was that I rose, dressed myself, and ever after was in better health than I had before enjoyed." By eyewitness affidavit accounts, she then got out of bed, got dressed, and walked downstairs to the parlor to meet with her surprised and concerned friends who were gathered there with the minister. Eddy called this "the falling apple that led [her] to the discovery" of Christian Science, but she said that she did not understand it at first, and that she spent three years afterwards studying the Bible in order to understand better how she had been healed. Although Cushing had not visited Eddy on that Sunday, on Monday Cushing visited her again to check up.
=== 1. CAL vs. Pseudopocket === Clinical attachment loss refers to the loss of periodontal attachment due to apical migration of the junctional epithelium (JE), accompanied by destruction of gingival connective tissue fibers and periodontal ligament fibers. This results in the formation of a true periodontal pocket, where the base of the pocket lies apical to the cementoenamel junction (CEJ). CAL develops through a complex host–microbial interaction, beginning with microbial dysbiosis, commonly involving anaerobic pathogens such as Porphyromonas gingivalis. This dysbiotic biofilm triggers an exaggerated host immune response, characterized by neutrophil infiltration, pro-inflammatory cytokine release, and complement activation. With chronic inflammation, destructive enzymes such as matrix metalloproteinases are activated, leading to the breakdown of gingival connective tissue fibers and detachment from the cementum. This allows the JE to migrate apically, deepening the periodontal pocket and facilitating further bacterial invasion. Simultaneously, inflammatory mediators stimulate RANKL-mediated osteoclast activation, resulting in alveolar bone resorption. Biologically, this process is irreversible, involving permanent breakdown of the JE, connective tissue fibers, periodontal ligament, and supporting bone. Clinically, CAL is the gold standard for diagnosing periodontitis and marks the transition from gingivitis to established periodontal disease. In contrast, a pseudopocket is characterized by increased probing depth without attachment loss.
Sources: en.wikipedia.org
A number of studies has now demonstrated that aqueous exposure to components within the UCM can affect the health of marine organisms, including possible hormonal disruption, and high concentrations of environmental UCMs have been strongly implicated with impaired health in wild populations.
Jerry Andrus (1918–2007) – magician Mike Barrett (born 1968) – TV announcer of the NBA Charles B. Bellinger (1839–1905) – federal district court judge, editor of the State Rights Democrat (now the Albany Democrat-Herald) Charles Burggraf Architect that spent most of his professional career in Albany. Dyrol Burleson 1500 m Olympian George Earle Chamberlain (1854–1928) – 11th Governor of Oregon Daveigh Chase (1990-2026) – actress Abigail Scott Duniway (1834–1915) – writer, newspaper publisher, and women's rights advocate Neil Elshire – former NFL defensive end, Minnesota Vikings Members of Falling Up – Christian rock band Alan L. Hart (1890–1962) – physician and novelist, raised in Albany Glenn L. Jackson (1902-1980) - Businessman and Chairman of the Oregon State Highway Commission Dave Johnson (born 1963) – Olympic athlete and former West Albany High School teacher Percy R. Kelly (1870–1949) – American attorney and jurist in the state of Oregon Ardyth Kennelly (1912–2005) – novelist Frank Morse (born 1943) – politician Sam Shoen (1916–1999) – founder of U-Haul Corp., operated a barbershop in the St. Francis Hotel at First Ave. and Ferry St. while a student at Oregon State College in the early 1940s. Delazon Smith (1816–1860) – politician Elmo Smith (1909–1968) – 27th Governor of Oregon Evelyn Waldren (1908–1986) – aviation pioneer James K. Weatherford (1850–1935) – Speaker of the Oregon House of Representatives (1876) and State Senator Mae Yih (born 1928) – member of the Oregon Legislative Assembly
=== Pros and cons === Osmotic release systems have a number of major advantages over other controlled-release mechanisms. They are significantly less affected by factors such as pH, food intake, GI motility, and differing intestinal environments. Using an osmotic pump to deliver drugs has additional inherent advantages regarding control over drug delivery rates. This allows for much more precise drug delivery over an extended period of time, which results in much more predictable pharmacokinetics. However, osmotic release systems are relatively complicated, somewhat difficult to manufacture, and may cause irritation or even blockage of the GI tract due to prolonged release of irritating drugs from the non-deformable tablet.
The amino acid positions of population variants and variants with known clinical relevance in the Ensembl Variation database as well as predicted benign and pathological variants from AlphaMissense can also be displayed.. The Interaction resource focuses on various aspects of human protein interactions, including reported experimental protein-protein interactions and their prediced three-dimensional structures as well as metabolic interactions and pathways. The data is based on external sources complemented with "in-house" analysis. Here you can explore: - Predicted 3D structures for consensus protein-protein interactions - Protein-protein interaction networks for most genes - Features such as subcellular location and expression specificity displayed on the interaction networks - Pathways/subsystems of metabolic genes and metabolic pathways from the Metabolic Atlas.
Sources: en.wikipedia.org
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.
Very few controlled human studies focus on the seven-residue sequence itself. Most clinical data concern the full-length protein in cardiac or ophthalmic settings. Conclusions drawn for one form should not be assumed to transfer to the other.
Detection normally relies on reversed-phase liquid chromatography paired with mass spectrometry. Chromatographic retention time establishes the expected elution window, and the mass spectrum confirms the molecular ion. Immunoassays exist but can cross-react with related peptides.
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.